Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Haematological cancer

Abnormal chromosomes forecast rapid disease progression in SMM

Nature Reviews Clinical Oncology volume 10, page 671 (2013)Cite this article

Subjects

Smouldering multiple myeloma (SMM) is an asymptomatic disorder of plasma cells that has a high risk of progression to symptomatic (active) myeloma.

From the analysis of samples from 248 patients with SMM, Kai Neben and colleagues now report that genetic aberrations such as deletion of the short arm of chromosome 17 (del17p), chromosomal translocation t(4;14), gain of the long arm of chromosome 1 (+1q21), and hyperdiploidy are adverse prognostic factors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Neben, K. et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Cin. Oncol. 10.1200/JCO.2012.48.4923

Download references

Authors
  1. Alessia Errico
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Errico, A. Abnormal chromosomes forecast rapid disease progression in SMM. Nat Rev Clin Oncol 10, 671 (2013). https://doi.org/10.1038/nrclinonc.2013.214

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.214

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer